Tanya E. Froehlich, MD, MS, FAAP

Pediatrician, Division of Developmental and Behavioral Pediatrics

Director of Research Training, Division of Developmental and Behavioral Pediatrics

Associate Director of Developmental and Behavioral Pediatrics Fellowship

Academic Affiliations

Associate Professor, UC Department of Pediatrics

Phone 513-803-1948

Fax 513-636-4402

Email tanya.froehlich@cchmc.org

ADHD; learning disabilities.

Tanya Froehlich, MD, MS, is a developmental-behavioral pediatrician whose research focuses on attention-deficit/hyperactivity disorder (ADHD). Her publications have investigated the prevalence of ADHD, ADHD medication use, and preschool psychotropic medication use. She also studies the contribution of environmental exposures (e.g., lead, tobacco, and pesticides) to ADHD etiology, and has served as co-investigator on a National Institute of Environmental Health Sciences R01 grant examining the effects of pyrethroid pesticide exposure on ADHD symptoms. In addition, Dr. Froehlich is working to identify predictors of ADHD medication response, and received a National Institute of Mental Health (NIMH) K23 Award to investigate this topic. Currently, she is the principal investigator on an NIMH-funded R01 aimed at characterizing effects of abrupt methylphenidate discontinuation, including evaluating genetic and phenotypic moderators of effect.

In addition, Dr. Froehlich has a strong interest in interprofessional training and mentoring. She is site principal investigator for a state-funded grant whose mission is train professionals from a variety of disciplines to provide enhanced care for families on Ohio Medicaid, with a special emphasis on care of developmental and mental health conditions. Dr. Froehlich is also supervisor for a Leadership Education in Neurodevelopmental Disabilities (LEND) interdisciplinary project which focuses on elucidating the needs of families in homeless shelters. Furthermore, Dr. Froehlich serves as associate director of the Developmental and Behavioral Pediatrics Fellowship as well as the director of research training for the Cincinnati Children’s Division of Developmental and Behavioral Pediatrics.

MD: Yale University School of Medicine, 1999.

MS: Epidemiology, University of Cincinnati, 2007.

Pediatric Intern: Children’s Hospital of Philadelphia, 1999-2000.

Pediatric Resident: Children’s Hospital of Philadelphia, 2000-2002.

Fellowship: Developmental and Behavioral Pediatrics, Cincinnati Children’s Hospital Medical Center, 2002-2005; General Pediatrics National Research Service Award Fellow, Cincinnati Children’s Hospital Medical Center, 2004-2007.

View PubMed Publications

Wagner-Schuman M, Richardson JR, Auinger A, Braun JM, Lanphear BP, JN Epstein, Yolton K, Froehlich TE. Association of Pyrethroid Pesticide Exposure with Attention-Deficit/Hyperactivity Disorder in a Nationally Representative Sample of U.S. Children. Environmental Health. 2015;14:44.

Barnard H, Roshni R, Xu Y, Froehlich TE, Epstein JN, Lanphear BP, Yolton K. Association of the Conner’s Kiddie Continuous Performance Test (K-CPT) Performance and Parent-Report Measures of Behavior and Executive Functioning. Journal of Attention Disorders. 2015 Apr 6.

Brinkman WB, Epstein JN, Auinger P, Tamm L, Froehlich TE. Association of Attention-Deficit/Hyperactivity Disorder and Conduct Disorder with Early Tobacco and Alcohol Use. Drug and Alcohol Dependence. 2015; 147:183-9.

Froehlich TE, Antonini TN, Brinkman WB, Langberg JM, Simon JO, Adams R, Fredstrom B, Narad ME, O’Brien KM, Altaye M, Matheson H, Tamm L, Epstein JN. Mediators of Methylphenidate Effects on Math Performance in Children with Attention-Deficit/ Hyperactivity Disorder. Journal of Developmental and Behavioral Pediatrics. 2014:35(2):100-7.

Froehlich TE, Delgado SV, Anixt JS. Focus on the Expanding Medication Options for Pediatric ADHD. Current Psychiatry. 2013:12(12):20-29.

Chirdkiatgumchai V, Xiao H, Fredstrom BK, Adams RE, Epstein JN, Shah SS, Brinkman WB, Kahn RS, and Froehlich TE. National Trends in Psychotropic Medication Use in Very Young Children: 1994-2009. Pediatrics. 2013;132:615-623.

Froehlich TE, Epstein JN, Nick TG, Melguizo Castro MS, Stein MA, Brinkman WB, Graham AJ, Langberg JM, Kahn RS. Pharmacogenetic Predictors of Methylphenidate Dose-Response in Attention-Deficit/Hyperactivity Disorder. Journal of the American Academy of Child and Adolescent Psychiatry. 2011;11:1129-1139.

Froehlich TE, McGough JJ, Stein MA. Progress and Promise of ADHD Pharmacogenetics. CNS Drugs. 2010;24:99-117.

Froehlich TE, Lanphear BP, Auinger P, Hornung R, Epstein JN, Braun J, Kahn RS. The Association of Tobacco and Lead Exposure with Attention-Deficit/Hyperactivity Disorder in a National Sample of U.S. Children. Pediatrics. 2009;124:e1054-63.

Froehlich TE, Lanphear BP, Epstein JN, Barbaresi WJ, Katusic SK, Kahn RS. Prevalence and Treatment of ADHD in a National Sample of U.S. Children. Archives of Pediatrics and Adolescent Medicine. 2007;161(9):857-864.

Better Outcomes for Children: Promoting Excellence in Healthcare Genomics to Inform Policy. Co-Investigator. National Human Genomic Research Institute. 2015-2019.

Neurobehavioral Effects of Abrupt Methylphenidate Discontinuation. Principal Investigator. National Institutes of Mental Health. 2014-2019.

The Effects of ADHD Medication (TEAM) Study. Principal Investigator. Cincinnati Children's Hospital Medical Center Clinical Translational Research Center (CTRC) Funding. 2014-2019.

Partnerships that Promote Integrated, Multidisciplinary Training Models and Increase Healthcare Access for the Ohio Medicaid Population. Site Principal Investigator. Ohio Department of Medicaid Technical Assistance Policy Program (MEDTAPP). 2015-2017.